#Cambridge #United Kingdom #Eli Lilly #Alchemab #ATLX-1282

Alchemab Therapeutics Initiates Phase 1 Clinical Trial of ATLX-1282 and Secures Additional Funding

Alchemab Therapeutics, a promising player in the biopharmaceutical landscape, is making headlines as it embarks on a Phase 1 clinical trial of its innovative therapy, ATLX-1282. This milestone follows the successful completion of pre-clinical trials and comes with an exciting announcement regarding a significant financing round.

The Start of a New Journey

On September 9, 2025, the company reported the initiation of this first-in-human trial, a critical step that signifies the transition from laboratory to clinical setting. This development marks a notable achievement for Alchemab, especially as ATLX-1282 was previously part of a licensing agreement with Eli Lilly and Company. Under this agreement, a milestone payment was made to Alchemab upon the commencement of this trial, clearly demonstrating the faith that Eli Lilly has in Alchemab's potential.

This collaboration allows Alchemab to maintain expertise in conducting the trial while Eli Lilly assumes responsibility for further development and commercialization. With both companies working towards a shared goal, the potential for ATLX-1282 to transform patient care is promising.

Significant Financial Backing

In conjunction with the trial announcement, Alchemab also revealed a $32 million extension to its Series A financing, which now totals $114 million. This funding round saw participation from a luminary list of investors, including Ono Venture Investment, which alongside other established investors like RA Capital and SV Health Investors, demonstrates robust support for Alchemab’s vision.

This additional capital is intended to bolster the progress of ATLX-2847, another groundbreaking program aimed at treating muscle atrophy. Alchemab’s AI-driven platform is essential in identifying protective auto-antibodies from resilient individuals, which are critical to their drug discovery initiatives.

A Revolutionary Approach to Drug Discovery

Alchemab's mission pivots on utilizing their proprietary AI-enabled platform to revolutionize drug discovery. This technology not only identifies auto-antibodies from individuals resilient to diseases but also explores novel therapeutic targets from these antibodies. Their DataCube, a comprehensive database of over 6,000 patient samples, serves as a critical resource in their quest to understand immune responses across various conditions.

Looking Ahead

The validation of Alchemab’s approach is manifested in their progress, as commented on by key figures within the company. Kate Bingham, Chair of Alchemab and Managing Partner at SV Health Investors, expressed her enthusiasm for reaching this funding milestone. Meanwhile, Jane Osbourn, Alchemab’s CEO, highlighted the significance of moving their first drug candidate into clinical trials as a testament to their cutting-edge platform.

With the backing of Eli Lilly and a solid network of investors, Alchemab is well-positioned to push forward not just with ATLX-1282 but also with other innovative programs targeting immune and neurological conditions.

“Working alongside Eli Lilly has been an incredible experience, and we eagerly anticipate the clinical performance of ATLX-1282,” stated Mike Hutton, Senior Vice President at Lilly.

Conclusion

As Alchemab Therapeutics moves forward with its clinical trial and enhances its funding capabilities, the potential for breakthroughs in treatment for hard-to-treat diseases becomes more tangible. The intersection of innovative technology, collaborative partnerships, and dedicated research embodies the future of medicine, driving the promise of improved health outcomes for patients worldwide. Alchemab is truly at the forefront of this transformational journey in the biopharmaceutical industry.